CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Yseop›
Library
Yseop

Yseop

Yseop builds regulatory-grade generative AI for medical writing and submission-ready content in life sciences.

HQ
Paris, FR
Founded
2008
Loading
Overview
Compare
Employees
News
Library

Yseop - Library

Official pages and third-party coverage in one index.

yseop.com·35 items across 29 mapped pages · Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

6 pages
  1. Automate Medical Regulatory Authoringworkflows/automate-medical-regulatory-authoringworkflows

    Welcome to Yseop Copilot Automate compliant document generation across clinical, safety, and CMC workflows—directly in Microsoft Word and Veeva Vault. Yseop Copilot is the most advanced regulatory writing platform, streamlining everything from narrative generation to final submission. Built for scale, Copilot supports the world’s top life sciences teams. Regulatory Document Coverage Across eCTD Modules Regulatory […]

  2. Compose/solutions/compose

    Compose is a fully custom NLG offering that can be tailored to your business's specific needs for accurate, customizable, and auditable content.

  3. Customers/customers

    Yseop's partners provide access to NLG technology and amplify its deployment across the globe. Learn more about the benefits of partnership here!

  4. Medical Writing Automation/medical-writing-automation

    Medical Writing Automation Increase efficiencies and productivity by automating core reporting tasks for medical writing. Yseop Copilot automates time-consuming tasks to enable regulatory documents to be delivered faster and more efficiently. By producing first drafts of reports like the clinical study report (CSR) and clinical trial narrative (CTN), medical writing teams can focus on scientific, […]

Blog

6 pages
  1. 5 Trends for a Leading CFO in a Post-Pandemic World/blog/5-trends-for-a-leading-cfo-in-a-post-pandemic-world

    Since the onset of the COVID-19 pandemic, CFO’s and their respective financial teams have been forced to digitally transform at unprecedented rates, whether prepared or not.

  2. Podcast: Passionate Pioneers/blog/podcast-passionate-pioneers

    We invite you to listen to this podcast featuring Emmanuel Walckenaer.

  3. Resources/resources

    Learn how Yseop's Natural Language Generation innovations are advancing here through our collection of whitepapers, case studies, blogs, podcasts, and more!

  4. Whitepaper: Harness the Power of Generative AI in Pharma/whitepaper-harness-the-power-of-generative-ai-in-pharma2

Press

6 pages
  1. Future of generative AI in pharma/news-and-press-releases/future-of-generative-ai-in-pharma

    Across all industries, generative AI has become the latest buzz word. This article looks at the future of generative AI in pharma.

  2. News & Press Releases/news-press-releases

    News & Press Releases Read More Read More Read More

  3. Possible Failures of ChatGPT/news-and-press-releases/possible-failures-of-chatgpt

    Companies should focus on a human-centric approach to avoid possible failures of ChatGPT and other LLM implementations

  4. The Top 10 Natural Language Generation Companies in 2023/news-and-press-releases/the-top-10-natural-language-generation-companies-in-2023

    The top natural language generation companies in 2023. NLG has become popular in recent years due to its content creation ability.

Careers & Hiring

1 page
  1. Careers/about/careers

    Discover where you can advance your career and your technical knowledge, here at the forefront of the digital working revolution at Yseop.

Comparison

1 page
  1. Yseop Copilot vs. Traditional LLMs/blog/yseop-copilot-vs-traditional-llms

    Uncover what sets Yseop Copilot apart from traditional LLMs like ChatGPT and embrace the power of pre-trained generative AI models (LLMs).

Team

1 page
  1. Leadership/about/leadership

    Yseop's leadership team consists of professionals across the spectrum of industries who passionately pursue the their vision of a thriving future through AI technologies.

About

1 page
  1. About/about

    Learn more about the company that is pioneering the most disruptive technological innovation on the horizon: Natural Language Generation.

Contact

3 pages
  1. Contact/contact

    If you're interested in learning more about Natural Language Generation or have questions about our products or the work we do, don't hesitate to reach out!

  2. Contact Thank You/contact/thank-you

    Thank You! Thank you for contacting us! Someone from our team will get back to you with a response as quickly as possible. Back Home Case Studies At the forefront of innovations and developments in AI and NLG. December 21, 2022 Whitepapers View More Case Studies

  3. Demo/get-a-demo

    Discover how Yseop's Regulatory-Grade AI can accelerate regulatory submissions by months: request a demo now.

Homepage

1 page
  1. Homepage/

    Yseop's produces submission-ready documents — with the accuracy, traceability, and control required for regulatory approval.

Privacy

2 pages
  1. Cookie Policy/cookie-policy

    View a list of all the cookies currently in use on Yseop's website with detailed information about each tracker and your online privacy.

  2. Privacy Policy/privacy-policy

    View Yseop’s privacy policy as it pertains to the web pages located at www.yseop.com to learn the ways it gathers, uses, and manages collected data.

Terms & Conditions

1 page
  1. Terms & Conditions/terms-conditions

    This webpage describes the terms and conditions applicable to a user's access and use of the web pages located within www.Yseop.com.

Not yet classified

1 page
  1. yseop.com/

    Yseop's produces submission-ready documents — with the accuracy, traceability, and control required for regulatory approval.

Coverage

5 items
  1. Yseop named to Fast Company's 2026 World Changing Ideas listyseop.com/news-and-press-releases/yseop-named-fast-company-2026-world-changing-ideas/

    Yseop is named to Fast Company's 2026 World Changing Ideas list. Fast Company recognizes organizations that make a difference in the world through the list, and Yseop is included among the organizations recognized in the 2026 edition of its World Changing Ideas list.

    Jun 2026 · YseopNews article

  2. Yseop featured in mind Health on accelerating drug approvals with regulatory-grade AImind.eu.com/health/article/pierre-louis-durel-yseop-dici-2027-notre-objectif-est-datteindre-un-gain-de-deux-a-trois-mois-sur-la-soumission-finale-dune-demande-damm/

    Yseop VP of Strategy and Operations Pierre-Louis Durel discusses how regulatory-grade AI is transforming regulatory writing. He links these changes to faster access to new therapies.

    Apr 2026 · mind HealthNews article

  3. TIME names Yseop Copilot one of the Best Inventions of 2025yseop.com/news-and-press-releases/time-names-yseop-copilot-one-of-the-best-inventions-of-2025/

    TIME names Yseop Copilot to its list of the 200 Best Inventions of 2025. The AI tool drafts compliant regulatory content for pharma teams.

    Oct 2025 · YseopNews article

  4. Claret Capital Partners announces EUR 10M growth funding in Yseopyseop.com/news-and-press-releases/claret-capital-partners-announces-e10m-growth-funding-in-yseop-to-scale-generative-ai-platform-for-life-sciences-and-pharma/

    Claret Capital Partners announces a EUR 10 million growth investment in Yseop, intended to support the company's international expansion and development of its regulatory content platform. The announcement frames the investment as growth funding for Yseop's work on that platform.

    Sep 2025 · YseopNews article